The review found no eligible studies for this question.
Levamisole showed no clear difference in adverse effects: infection compared with cyclophosphamide (low certainty).
Levamisole showed no clear difference in adverse effects: leucopenia compared with cyclophosphamide (low certainty).
It is very uncertain whether levamisole changes adverse effects: abnormal liver function tests compared with cyclophosphamide (very low certainty).
Intravenous may leads to lower relapse at 6 months compared with oral cyclophosphamide (low certainty).
Intravenous may leads to lower continuing frequently‐relapsing or steroid‐dependent SSNS at 6 months compared with oral cyclophosphamide (low certainty).
Intravenous showed no clear difference in relapse at end of study compared with oral cyclophosphamide (low certainty).
The review found no eligible studies for this question.
Intravenous showed no clear difference in adverse events: leucopenia compared with oral cyclophosphamide (low certainty).
Intravenous showed no clear difference in adverse events: hair loss compared with oral cyclophosphamide (low certainty).
Intravenous may leads to lower adverse events: all infections compared with oral cyclophosphamide (low certainty).
It is very uncertain whether intravenous changes adverse events: nausea and vomiting compared with oral cyclophosphamide (very low certainty).
Rituximab showed no clear difference in death at 6 months compared with cyclophosphamide (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Rituximab showed no clear difference in remission at 6 months compared with cyclophosphamide (moderate certainty).
Rituximab showed no clear difference in relapse at 12 months compared with cyclophosphamide (low certainty).
Rituximab showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).
Rituximab showed no clear difference in serious Infections compared with cyclophosphamide (moderate certainty).
Mycophenolate mofetil showed no clear difference in death at 6 months compared with cyclophosphamide (low certainty).